Pharmaceuticals & Therapeutics

Strong Attruby sales and new data showing superiority fuel BridgeBio’s momentum as it prepares for three FDA decisions, backed by a new $1B financing.

Two years after a landmark rejection, the bid to approve MDMA-assisted therapy for PTSD is back. This is more than a resubmission; it's a test case for a new paradigm in medicine.

Indian pharma giant Lupin secures FDA approval for a generic heart drug, challenging AstraZeneca and signaling a new era of cost competition in specialty medicine.

Heron Therapeutics withdraws guidance after a patent blow to its top drug, forcing a strategic review. Can strong growth in new acute care products save it?

Amid its pending sale to Zymeworks, Theravance Biopharma’s Q2 results reveal a lesson in resilience, with strong YUPELRI sales and deep cost cuts.

Partner Ocumension submits NCX 470 for approval, a move poised to tap into a massive patient market and validate Nicox's global commercialization strategy.

Braveheart Bio's stunning IPO debut raised nearly half a billion dollars. We dig into the story behind the numbers and what it signals for the 2026 economy.

NRx Pharmaceuticals announces a key FDA milestone for its ketamine therapy. This is a critical step, but the path to patient access is complex.

For a rare brain disease with no cure, a revolutionary trial design offers a faster path to treatment and renewed hope for thousands of patients and families.

BioStem Technologies' move from OTC to Nasdaq marks a pivotal moment, promising greater capital access and visibility for its innovative perinatal allografts.

X4 Pharmaceuticals secures a key European approval and overhauls its pivotal trial, signaling a major strategic shift backed by a newly extended cash runway.

With late-stage trials underway and a cash runway into 2030, Trevi Therapeutics is accelerating its mission. But what does this mean for millions of unseen sufferers?

Artiva Biotherapeutics secures FDA fast-track status for its novel NK cell therapy, AlloNK. This could revolutionize autoimmune care for millions.

With a Q3 FDA submission for its novel epilepsy drug azetukalner imminent, Xenon leverages a massive cash runway to expand into neuropsychiatry and pain.

With a $215M war chest and a runway into 2028, Corvus Pharmaceuticals is aggressively advancing its lead drug, soquelitinib, across cancer and immune diseases.

A biotech firm has uncovered a self-perpetuating cycle that drives Alzheimer's from within the cell's mitochondria, and they've developed a drug to break it.

vTv Therapeutics is nearing a critical milestone with its oral drug for Type 1 diabetes. Can it solve a deadly problem while navigating the financial tightrope?

With new patents and a $300M war chest, Beren Therapeutics nears an FDA decision for its NPC drug. But can its public benefit model survive the high-risk biotech gauntlet?

A critical safety milestone for PepGen’s PGN-EDODM1 offers a glimmer of hope for myotonic dystrophy patients and highlights a novel strategy in a competitive field.

With a 32% jump in royalty revenue and a game-changing acquisition, Ligand Pharmaceuticals solidifies its market dominance. But is the growth sustainable?